

# CERTIFICATE

Survey of 28 October 2022

You have fulfilled the requirements of the External Quality Assessment with the following analysis

## Haemostasis 05 - AT, Protein C, Protein S, C1-Inhibitor (225):

Validity 12 months:

Antithrombin  
total Protein C

(R) analysis is subject to the RiliBÄK

**Participant:**  
2430  
MUDr. Martin Spacek, PhD.  
Vseobecna fakultni nemocnice v Praze  
Centralni hematologicke laboratore ULBLD  
U Nemocnice 2  
12808 Praha 2

Düsseldorf, 14 December 2022



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)



# CERTIFICATE OF PARTICIPATION

Survey of 28 October 2022

You have participated in the External Quality Assessment with the following analysis


## Haemostasis 05 - AT, Protein C, Protein S, C1-Inhibitor (225):

Antithrombin  
free Protein S funct. (act.)  
total Protein C

(R) analysis is subject to the RiliBÄK

**Participant:**  
2430  
MUDr. Martin Spacek, PhD.  
Vseobecna fakultni nemocnice v Praze  
Centralni hematologicke laboratore ULBLD  
U Nemocnice 2  
12808 Praha 2

Düsseldorf, 14 December 2022



Prof. Dr. med. Michael Spannagl  
(Head of Reference Institution)

